Astilbin

Cat. No.:	HY-N0509		
CAS No.:	29838-67-3		
Molecular Formula:	C ₂₁ H ₂₂ O ₁₁		
Molecular Weight:	450.39		
Target:	Keap1-Nrf2; TNF Receptor; NF-кВ		
Pathway:	NF-κB; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (222.03 mM; Need ultrasonic) H ₂ O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)				
Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2203 mL	11.1015 mL	22.2030 mL
	5 mM	0.4441 mL	2.2203 mL	4.4406 mL	
		10 mM	0.2220 mL	1.1101 mL	2.2203 mL
	Please refer to the sol	ubility information to select the ap	propriate solvent.		
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution				

BIOLOGICAL ACTIVITY			
Description	Astilbin is a flavonoid compou activation.	und and enhances NRF2 activation. Astilbin also suppresses TNF- $lpha$ expression and NF- κ B	
IC ₅₀ & Target	NRF2	NF-κB	
In Vitro	Astilbin is a common dietary f	lavonoid that can be found in various kinds of herbs and foods such as Smilax Glabra,	



0 όн

HO

.OH

ΟН

ЮΗ





	Sarcandra glabra, grape and red wine. Astilbin markedly inhibits cisplatin-induced cell apoptosis and recovers cell growth. Astilbin significantly decreases reactive oxygen species (ROS) accumulation and alleviates ROS-induced activation of p53, MAPKs and AKT signaling cascades, which in turn attenuates cisplatin-induced HEK-293 cell apoptosis. Astilbin effectively enhances NRF2 activation and transcription of its targeting antioxidant genes to reduce ROS accumulation in cisplatin- induced HEK-293 cells. Astilbin obviously suppresses tumor necrosis factor alpha (TNF-α) expression and NF-κB activation, and also inhibits the expression of induced nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). To measure the effects of Astilbin on the growth of CDDP-treated renal cells, HEK-293 cells are treated with CDDP (100 μM) and/or Astilbin (200 μM). Astilbin treatment significantly improvescell growth in CDDP-induced HEK-293 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	To explore whether Astilbin improves CDDP-induced nephrotoxicity in vivo, an acute cisplatin nephrotoxic mouse model is established. Single injection of CDDP with 8 mg/kg dose results in notable weight loss compared with control group. However, the phenomenon is significantly alleviated by Astilbin at dose of 50 mg/kg. The mice fed Astilbin alone do not show any obvious alteration in body weight. Similarly, serum creatinine (SCr) and blood urea nitrogen (BUN) are higher in CDDP-treated mice than in control group. Treatment with Astilbin also decreases SCr and BUN levels. To examine the protective effect of Astilbin on CDDP-induced renal histopathological damage, the mouse kidney sections are stained with H&E. The mice in control group and Astilbin treated group have normal kidney morphology, while kidneys in CDDP group show severe damage with tubular degeneration, necrosis and cystic dilatation of the tubules with focal hemorrhages. Administration of Astilbin mitigated kidney injury, resulting in lower histopathological score compared to CDDP group. The apoptosis of renal cells is also detected using TUNEL staining to determine whether Astilbin treatment decreased renal cell apoptosis in CDDP-induced acute nephrotoxic mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ΡΡΟΤΟΓΟΙ	·
PROTOCOL	
Cell Assay ^[1]	HEK-293 cells are seeded into 96-well plate with a density of 5 × 10 ⁴ cells/well and subsequently treated with CDDP, Astilbin (0, 10, 30, 50, 100, 200 and 300 μM) or CDDP+Astilbin for 24 h. After treatments, 20 μL of 5 mg/mL MTT is added to each well. The cells are incubated for additional 4 h at 37°C. Then cell supernatant is abandoned and 100 μL of formanzan is added to each well. The plate is shaken at room temperature for 15 min. Spectrophotometric absorbance is measured by Synergy Microplate Reader at 570 nm ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice ^[1] Male C57BL/6 mice (20-24 g, 8 weeks of age) are used. After acclimation for one week, the experimental mice are randomly divided into 4 groups with 10 animals per group: control group, CDDP group, CDDP+Astilbin group and Astilbin group. The control group and CDDP group are orally administered saline for 10 days; the CDDP+Astilbin group and Astilbin group are orally administered 50 mg/kg Astilbin for 10 days. The CDDP group and CDDP+Astilbin group receive a single intraperitoneal injection of CDDP on the 7th day of the experiment, while control group and Astilbin group receive saline injection on the same day ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Phytother Res. 2023 Dec 28.
- Front Pharmacol. 2022 May 16;13:848957.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Wang SW, et al. Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation. Food Chem Toxicol. 2018 Apr;114:227-236.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA